Filing Details

Accession Number:
0001144204-18-014203
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-03-12 19:26:28
Reporting Period:
2018-03-08
Accepted Time:
2018-03-12 19:26:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1023024 Ani Pharmaceuticals Inc ANIP Pharmaceutical Preparations (2834) 582301143
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1579618 Tracy Marshbanks C/O Ani Pharmaceuticals, Inc.
210 Main Street West
Baudette MN 56623
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2018-03-08 15,391 $63.08 534,543 No 4 S Indirect See Footnote
Common Stock Disposition 2018-03-09 36,561 $63.01 497,982 No 4 S Indirect See Footnote
Common Stock Disposition 2018-03-12 12,269 $63.03 485,713 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
Footnotes
  1. This transaction was executed in multiple trades at prices ranging from $63.00 to $63.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  2. This transaction was executed in multiple trades at prices ranging from $63.00 to $63.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. This transaction was executed in multiple trades at prices ranging from $63.00 to $63.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. Held by FA Private Equity Fund IV, L.P., FA Private Equity Fund IV GmbH & Co. Beteiligungs KG, The Productivity Fund IV Liquidating Trust, and The Productivity Fund IV Advisors Fund Liquidating Trust, which the Reporting Person may be deemed to be a beneficial owner pursuant to rule 16a-1(a)(1)